These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15866681)

  • 1. Valsartan-induced hematocrit changes in renal transplant patients.
    Flores CA; Ardiles LG; Aros CA; Muñoz CC; Schneider HO; Ramírez JA; Jerez V; Valderrama MG; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1586-8. PubMed ID: 15866681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
    Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
    Formica RN; Friedman AL; Lorber MI; Bia MJ
    Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
    Durmus A; Dogan E; Erkoc R; Sayarlioglu H; Topal C; Dilek I
    Int J Clin Pract; 2005 Sep; 59(9):1001-4. PubMed ID: 16115171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
    Basri N; Gendo MZ; Haider R; Abdullah KA; Hassan A; Shaheen FA
    Exp Clin Transplant; 2007 Jun; 5(1):607-9. PubMed ID: 17617052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
    Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
    Rodríguez Pérez JC; Novoa Novoa J; Caballero A; Anabitarte A; Plaza C; Palop L; Rodríguez Esparragón F
    Nefrologia; 2005; 25(5):500-8. PubMed ID: 16392299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ando N; Ohta S; Yoshii M; Inada H; Tsukada K; Minami J; Ono H; Matsuoka H
    Hypertens Res; 2005 Nov; 28(11):865-70. PubMed ID: 16555574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.